Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579374 | 0.84 | POLB (1.00) | POLBL3MBTL1ALDH1A1TDP1CASP3 | |
| SCHEMBL19329397 | 0.82 | POLB (0.64) | POLBL3MBTL1ALDH1A1TDP1CASP3 | |
| SCHEMBL14740993 | 0.79 | POLB (0.63) | POLBL3MBTL1ALDH1A1TDP1CASP3 | |
| SCHEMBL14661066 | 0.78 | NUDT1 (0.52) | POLBL3MBTL1ALDH1A1TSHRKMT2A | |
| SCHEMBL4132618 | 0.78 | ALDH1A1 (0.64) | POLBL3MBTL1ALDH1A1TDP1CASP3 | |
| SCHEMBL24308561 | 0.77 | ALDH1A1 (0.63) | POLBL3MBTL1ALDH1A1TDP1CASP3 | |
| SCHEMBL27957250 | 0.77 | POLB (0.56) | POLBL3MBTL1ALDH1A1TDP1CASP3 | |
| SCHEMBL30658108 | 0.77 | EGLN1 (0.56) | POLBL3MBTL1ALDH1A1TDP1CASP3 | |
| SCHEMBL27976971 | 0.77 | POLB (0.59) | POLBL3MBTL1ALDH1A1TDP1CASP3 | |
| SCHEMBL25120653 | 0.76 | POLB (0.56) | POLBL3MBTL1ALDH1A1TDP1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4959096-A | SUBSTITUTED ISONICOTINIC ACID ESTERS | CIBA-GEIGY CORPORATION (US) | 1990-09-25 | — | — | US | claimed |
| EP-3426350-B1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-30 | — | — | EP | disclosed |
| EP-3426350-B1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-30 | — | — | EP | disclosed |
| US-10745380-B2 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2020-08-18 | — | — | US | disclosed |
| US-10745380-B2 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY LTD (AU) | 2020-08-18 | — | — | US | disclosed |
| US-20200039956-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-02-06 | — | — | US | disclosed |
| US-20200039956-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-02-06 | — | — | US | disclosed |
| EP-3426350-A1 | PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153521-A1 | PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153521-A1 | PYRIDINE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039956-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | HBB, HBG2, HCCS | POLB 471/4885L3MBTL1 579/4885ALDH1A1 1067/4885 |
| US-10745380-B2 | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBG2, HCCS | POLB 471/4885L3MBTL1 579/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.